Search alternatives:
significant based » significant cause (Expand Search), significant barrier (Expand Search), significant burden (Expand Search)
based decrease » caused decreased (Expand Search), marked decrease (Expand Search), based defense (Expand Search)
long decrease » point decrease (Expand Search), nn decrease (Expand Search), fold decrease (Expand Search)
_ decrease » _ decreased (Expand Search), _ decreasing (Expand Search)
significant based » significant cause (Expand Search), significant barrier (Expand Search), significant burden (Expand Search)
based decrease » caused decreased (Expand Search), marked decrease (Expand Search), based defense (Expand Search)
long decrease » point decrease (Expand Search), nn decrease (Expand Search), fold decrease (Expand Search)
_ decrease » _ decreased (Expand Search), _ decreasing (Expand Search)
-
1
Nineteen SNPs with significant association (<i>P < </i>5 × 10<sup>−8</sup>) with risk on minJSW decrease in knee OA.
Published 2025“…<p>Nineteen SNPs with significant association (<i>P < </i>5 × 10<sup>−8</sup>) with risk on minJSW decrease in knee OA.…”
-
2
Validation of genetic markers for risk of OA or knee OA for decrease in minJSW.
Published 2025“…The red line represents the significance threshold (<i>P < </i>5 × 10<sup>−8</sup>). …”
-
3
Voxel-based whole-hemisphere analysis shows regional and dose-dependent decrease of microglia.
Published 2025“…<p>(A) Each 3-dimensional map of statistically affected voxels (p < 0.05, with the red scale, representing the significance in decrease of microglia, and the cyan scale, representing the increase in microglia; reference atlas is grey) summarizes all the treated and control samples within a cohort (3 samples per group). …”
-
4
-
5
Voxel-based whole-brain analysis shows regional and dose-dependent effects of netoglitazone in decreasing plaque count.
Published 2025“…(D) Long-term treatment with a high dose of netoglitazone demonstrates a considerable decrease in plaque count, especially in the olfactory, striatum, pallidum, hindbrain, and midbrain regions.…”
-
6
-
7
-
8
-
9
-
10
Voxel-based whole-brain analysis shows regional and dose-dependent effects of netoglitazone in decreasing plaque mean size.
Published 2025“…However, there is only a minimal effect on decreasing plaque size. (C) Short-term-treatment with a high dose of netoglitazone reveals a significant reduction in plaque size, especially observed in the hippocampus, striatum, thalamus, hypothalamus, midbrain, and hindbrain. …”
-
11
-
12
-
13
-
14
Statistically significant linear increase in use of antidepressants during the observed time period.
Published 2025Subjects: -
15
-
16
-
17
-
18
-
19
-
20